---
title: "SIM0725 has been approved by the National Medical Products Administration to conduct clinical… — 先聲藥業集團 — DecisionGateway"
description: "investigation by 先聲藥業集團, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d"
meta:
  "og:description": "investigation by 先聲藥業集團, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "SIM0725 has been approved by the National Medical Products Administration to conduct clinical… — 先聲藥業集團 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

investigation

# **SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.**

A investigation by [**先聲藥業集團**](https://dgw.tmarket.io/actors/01a1d903-deb0-7451-9aea-911c778a672b). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *已獲國家藥品監督管理局批准在中國開展臨牀試驗*

stockintelligencenewsPublished 2026-11-10 [ Read source](https://t.me/stockintelligencenews/5713659)

[**先聲藥業集團 dossier **](https://dgw.tmarket.io/actors/01a1d903-deb0-7451-9aea-911c778a672b)

## **Discussion**

## **Related claims**

[**SIM0725 was independently developed by the company.**先聲藥業集團 · statement](https://dgw.tmarket.io/claims/01a1d903-def4-7b63-8f8d-33fa088582cc) [**SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).**先聲藥業集團 · statement](https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381) [**SIM0725 is intended for the treatment of autoimmune diseases.**先聲藥業集團 · statement](https://dgw.tmarket.io/claims/01a1d903-dee5-7dfa-b463-3177957abb5f) [**Novo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.**诺和诺德 · statement](https://dgw.tmarket.io/claims/01a1d24c-483f-793d-9b6b-be462fc1a0f8) [**CagriSema is a fixed-dose combination formulation.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-484f-7573-9a2b-d53df4512e82) [**CagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.**界面新闻 · statement](https://dgw.tmarket.io/claims/01a1d24c-485a-7af6-9fa1-7aa87fd66188)

## **More claims by 先聲藥業集團**

[**SIM0725 was independently developed by the company.**statement](https://dgw.tmarket.io/claims/01a1d903-def4-7b63-8f8d-33fa088582cc) [**SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).**statement](https://dgw.tmarket.io/claims/01a1d903-deed-7a5c-ba12-ed328cc73381) [**SIM0725 is intended for the treatment of autoimmune diseases.**statement](https://dgw.tmarket.io/claims/01a1d903-dee5-7dfa-b463-3177957abb5f)

[All claims by 先聲藥業集團](https://dgw.tmarket.io/claims?claimant_id=01a1d903-deb0-7451-9aea-911c778a672b)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d#webpage","@type":"WebPage","description":"investigation by 先聲藥業集團, recorded recently — verbatim quote and source citation.","name":"SIM0725 has been approved by the National Medical Products Administration to conduct clinical… — 先聲藥業集團 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"SIM0725 has been approved by the National Medical Products…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d903-dedc-7f65-a559-750a8781566d#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/stockintelligencenews/5713659","text":"已獲國家藥品監督管理局批准在中國開展臨牀試驗","url":"/claims/01a1d903-dedc-7f65-a559-750a8781566d","spokenByCharacter":{"@type":"Person","name":"先聲藥業集團","@id":"/actors/01a1d903-deb0-7451-9aea-911c778a672b"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.